Pregnancy Favism and Severe Hemolytic Anemia in a Patient with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: A Case Report
Main Article Content
Abstract
Introduction: Favism is a genetic disease-causing hemolytic anemia in Mexico, primarily due to glucose-6-phosphate dehydrogenase (G6PD) deficiency. Factors triggering favism include infections, pregnancy, certain drugs, and eating beans. The disease is inherited recessively and is more common in men. Diagnosing and managing favism during pregnancy is crucial, as it can lead to severe hemolytic anemia and neonatal jaundice.
Case presentation: A female patient, aged 18, presented with severe anemia and thrombocytopenia during her 20-week pregnancy. During pregnancy, the patient experienced jaundice and anemia at 21.5 weeks of gestation. Despite not presenting evidence of bleeding, transfusions were performed due to critical hemoglobin levels. G6PD deficiency was confirmed at 9 days of hospital admission, indicating severe hemolytic anemia.
Clinical discussion: The hemolytic crisis in a pregnant woman with favism was triggered by pregnancy and repeated infections of candidiasis. Clinical symptoms of hemolysis were confirmed through G6PD and Coombs tests, and blood transfusion was recommended to prevent complications. The patient's hemoglobin was monitored for signs of active intravascular hemolysis, and a folic acid tablet was recommended during the crisis. Post-crisis management involved periodic controls of hemoglobin, hematocrit, lactate dehydrogenase, and bilirubin.
Conclusion: Favism, a prevalent condition in Mexico, should be considered in patients with a family history of hemolytic anemia or compatible symptoms. Early diagnosis and proper management are crucial to prevent complications in the mother and fetus. A multidisciplinary approach, genetic counseling, and medical education are essential for effective management.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Sánchez Sánchez, N. J., Acosta Benito, M. A., & Hernández Gómez, M. A. (2020). Déficit de glucosa-6-fosfato-deshidrogenasa (G6PD) en países occidentales. Revisión bibliográfica. Semergen, 46(1), 68–74.
https://doi.org/10.1016/j.semerg.2019.05.010
II. Nkhoma, E. T., Poole, C., Vannappagari, V., Hall, S. A., & Beutler, E. (2009). The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells, Molecules & Diseases, 42(3), 267–278. https://doi.org/10.1016/j.bcmd.2008.12.005
III. Luzzatto, L., Ally, M., & Notaro, R. (2020). Glucose-6-phosphate dehydrogenase deficiency. Blood, 136(11), 1225–1240.
https://doi.org/10.1182/blood.2019000944
IV. Dal Borgo A, P., Rosario, S. C., & Cavieres A, M. (2000). Dos nuevas mutaciones de glucosa 6 fosfato deshidrogenasa, G6PD Santiago y G6PD Calvo Mackenna. Revista Chilena de Pediatria, 71(5). https://doi.org/10.4067/s0370-41062000000500007
V. Dinarelli, S., Longo, G., Germanova-Taneva, S., Todinova, S., Krumova, S., & Girasole, M. (2022). Surprising structural and functional properties of favism erythrocytes are linked to special metabolic regulation: A cell aging study. International Journal of Molecular Sciences, 24(1), 637.
https://doi.org/10.3390/ijms24010637
VI. Bello Gutiérrez, P., & Mohamed Dafa, L. (2015). Déficit de glucosa-6-fosfato deshidrogenasa: revisión a propósito de un caso. Pediatría Atención Primaria, 17(68), 361–368.
https://doi.org/10.4321/s1139-76322015000500014
VII. Minucci, A., Antenucci, M., Giardina, B., Zuppi, C., & Capoluongo, E. (2010). G6PD Murcia, G6PD Ube and G6PD Orissa: Report of three G6PD mutations unusual for Italian population. Clinical Biochemistry, 43(13–14), 1180–1181. https://doi.org/10.1016/j.clinbiochem.2010.06.021
VIII. Beretta, A., Manuelli, M., & Cena, H. (2023). Favism: Clinical features at different ages. Nutrients, 15(2). https://doi.org/10.3390/nu15020343
IX. Luzzatto, L., Nannelli, C., & Notaro, R. (2016). Glucose-6-phosphate dehydrogenase deficiency. Hematology/Oncology Clinics of North America, 30(2), 373–393.
https://doi.org/10.1016/j.hoc.2015.11.006
X. Serrano Sepúlveda, M. C., Franco, H. L., Pulido Buitrago, A. M., Gómez León, E. J., & Saldaña Franco, S. (2022). Anemia hemolítica desencadenada por consumo de habas en un paciente con déficit de glucosa 6 fosfato deshidrogenasa: presentación de caso en pediatría. Universitas Médica, 63(4). https://doi.org/10.11144/javeriana.umed63-4.ahvf
XI. Gomez Casero, L., Ortiz Cansado, A., & Morales Blanco, P. (2006). Icterus, anemia, favism. Revista clinica espanola, 206(8), 415.
https://doi.org/10.1157/13090522
XII. Da Costa, L., Galimand, J., Fenneteau, O., & Mohandas, N. (2013). Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders. Blood Reviews, 27(4), 167–178.
https://doi.org/10.1016/j.blre.2013.04.003
XIII. Diegues, A., Simões, P., Ceriz, T., Lopes, A. R., & Tomé, E. (2022). Favism: A case report. Cureus, 14(3), e23269.
https://doi.org/10.7759/cureus.23269
XIV. Committee on Health Care for Underserved Women, American College of Obstetricians and Gynecologists. (2007). ACOG Committee Opinion No. 361: Breastfeeding: maternal and infant aspects. Obstetrics and Gynecology, 109(2 Pt 1), 479–480. https://doi.org/10.1097/00006250-200702000-00064